CytoMed Therapeutics (GDTC) Accumulated Depreciation & Amortization (2021 - 2025)
CytoMed Therapeutics (GDTC) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with $23070.2 as the latest value for Q4 2025.
- Quarterly Accumulated Depreciation & Amortization rose 144.39% to $23070.2 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23070.2 through Dec 2025, up 144.39% year-over-year, with the annual reading at $22885.4 for FY2025, 143.45% up from the prior year.
- Accumulated Depreciation & Amortization hit $23070.2 in Q4 2025 for CytoMed Therapeutics, up from $9440.1 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $23070.2 in Q4 2025 to a low of $1619.9 in Q4 2023.
- Historically, Accumulated Depreciation & Amortization has averaged $7556.5 across 5 years, with a median of $1851.1 in 2021.
- Biggest five-year swings in Accumulated Depreciation & Amortization: decreased 10.08% in 2023 and later surged 482.76% in 2024.
- Year by year, Accumulated Depreciation & Amortization stood at $1851.1 in 2021, then decreased by 2.68% to $1801.4 in 2022, then decreased by 10.08% to $1619.9 in 2023, then soared by 482.76% to $9440.1 in 2024, then surged by 144.39% to $23070.2 in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for GDTC at $23070.2 in Q4 2025, $9440.1 in Q4 2024, and $1619.9 in Q4 2023.